- Home
- BDRX vs ALLR Comparison
BDRX vs ALLR Comparison
Compare BDRX & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDRX
- ALLR
- Stock Information
- Founded
- BDRX 2000
- ALLR 2004
- Country
- BDRX United Kingdom
- ALLR United States
- Employees
- BDRX N/A
- ALLR N/A
- Industry
- BDRX Biotechnology: Pharmaceutical Preparations
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- BDRX Health Care
- ALLR Health Care
- Exchange
- BDRX Nasdaq
- ALLR Nasdaq
- Market Cap
- BDRX 3.6M
- ALLR 4.0M
- IPO Year
- BDRX N/A
- ALLR N/A
- Fundamental
- Price
- BDRX $1.15
- ALLR $0.85
- Analyst Decision
- BDRX
- ALLR
- Analyst Count
- BDRX 0
- ALLR 0
- Target Price
- BDRX N/A
- ALLR N/A
- AVG Volume (30 Days)
- BDRX 3.6M
- ALLR 564.6K
- Earning Date
- BDRX 04-11-2025
- ALLR 08-04-2025
- Dividend Yield
- BDRX N/A
- ALLR N/A
- EPS Growth
- BDRX N/A
- ALLR N/A
- EPS
- BDRX N/A
- ALLR N/A
- Revenue
- BDRX N/A
- ALLR N/A
- Revenue This Year
- BDRX N/A
- ALLR N/A
- Revenue Next Year
- BDRX N/A
- ALLR N/A
- P/E Ratio
- BDRX N/A
- ALLR N/A
- Revenue Growth
- BDRX N/A
- ALLR N/A
- 52 Week Low
- BDRX $1.01
- ALLR $0.61
- 52 Week High
- BDRX $41.50
- ALLR $17.35
- Technical
- Relative Strength Index (RSI)
- BDRX 39.66
- ALLR 39.03
- Support Level
- BDRX $1.01
- ALLR $0.78
- Resistance Level
- BDRX $1.26
- ALLR $0.93
- Average True Range (ATR)
- BDRX 0.12
- ALLR 0.07
- MACD
- BDRX 0.01
- ALLR -0.02
- Stochastic Oscillator
- BDRX 15.22
- ALLR 18.72
About BDRX Biodexa Pharmaceuticals plc
Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company focused on developing a pipeline of products to treat diseases that have unmet medical needs. These include familial adenomatous polyposis (FAP), non-muscle invasive bladder cancer (NMIBC), type 1 diabetes (T1D), and rare or orphan brain cancers.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine company. The company is actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. Its Drug Response Predictor (DRP) technology refines patient selection and improves clinical outcomes. Its pipeline product includes Dovitinib, Stenoparib, Ixempra, and other formulations.